IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction
28.10.2025 22:04:00 EET | Business Wire | Press release
IQM Quantum Computers, a global leader in superconducting quantum computers, today announced it will integrate NVIDIA’s NVQLink into its quantum computers to scale error correction, a key component for realising quantum computing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028095798/en/
IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction
NVQLink is an open and interoperable platform integrated with NVIDIA CUDA-Q that connects quantum hardware to AI supercomputing. It provides low-latency and high-throughput connectivity between quantum computers and Graphics Processing Unit (GPU)-accelerated compute, enabling the real-time orchestration of computational tasks needed for running useful hybrid quantum-classical applications and quantum error correction.
While today’s quantum computers are reaching sizes that unlock algorithms in simulation, optimization, and machine learning, errors at the level of physical qubits still prevent commercial quantum advantage.
IQM’s technology roadmap focuses on quantum error correction, which reduces error rates by encoding logical qubits in clusters of physical qubits. This requires longer runtimes, and more complex compute processes on GPUs. To support this path, IQM has pioneered IQM Constellation, a unique quantum processor architecture for scalable error correction.
The partnership combines IQM’s system integration know-how and advanced processor technology, Zurich Instruments’ control systems, and the NVIDIA accelerated computing platform with scaling compute power across the timescales involved from hundreds of nanoseconds to seconds. As a result, this collaboration establishes a layered compute architecture capable of supporting workloads.
“Integrating NVQLink into our systems is a significant step towards building logical qubits and utility-scale quantum computers,” said Jan Goetz, Co-CEO and Co-founder of IQM Quantum Computers. “By combining our IQM Constellation with NVIDIA accelerated computing and Zurich Instruments’ control electronics, we can tackle one of the toughest challenges on the road to fault-tolerant quantum computing: real-time decoding and control at scale.”
Beyond error correction, NVQLink also supports hybrid quantum–classical applications by allowing seamless data flow between logical qubits and classical compute resources. This opens up new opportunities for running hybrid algorithms that require real-time feedback from large-scale compute to superconducting quantum computers.
“Quantum is reaching an inflection point, and hybrid systems will be the foundation for solving real-world problems,” said Flavio Heer, CTO at Zurich Instruments. “Collaborating closely with IQM and NVIDIA to showcase seamless end-to-end integration of classical and quantum computing, spanning both hardware and software, represents a significant advancement for hybrid classical-quantum systems, and will enable powerful demonstrations very soon.”
"Building scalable quantum accelerated supercomputing demands tighter integration between quantum processors and classical accelerated computing to tackle challenges like quantum error correction," said Tim Costa, General Manager for Quantum at NVIDIA. "QPU builders like IQM and quantum system vendors like Zurich Instruments are accelerating breakthroughs in quantum computing by using NVIDIA NVQLink as the open unified interface connecting quantum hardware to accelerated computing platforms."
About IQM Quantum Computers:
IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centers, research labs, universities, and enterprises that have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea, and the United States. For more information, visit: meetiqm.com
About Zurich Instruments
Zurich Instruments is a Swiss company with a passion for phenomena that are often notoriously difficult to measure. We lead the change by providing advanced hardware, software and services for quantum computing control systems, lock-in amplifiers, impedance analyzers, and arbitrary waveform generators. As a company of scientists for scientists, we tackle challenges of research by delivering a wide product portfolio that reduces complexity of laboratory setups, unlocks new measurement strategies and complies to Swiss quality standards. Our commitment to collaborations and real-time support is reflected in seven offices worldwide, numerous research partnerships, and thousands of publications referring to Zurich Instruments. Since 2021, Zurich Instruments is a part of the Rohde & Schwarz and continues its scale up ambitions to advance science and accelerate the second quantum revolution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251028095798/en/
Contacts
Media contact:
Email: press@meetiqm.com
Mobile: +358504790845
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom